136 related articles for article (PubMed ID: 16681773)
1. Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas.
Murakami M; Tsukada H; Shida M; Watanabe M; Maeda H; Koido S; Hirasawa T; Muramatsu T; Miyamoto T; Nasu S; Yasuda S; Kajiwara H; Yasuda M; Ide M
Int J Gynecol Cancer; 2006; 16(2):854-60. PubMed ID: 16681773
[TBL] [Abstract][Full Text] [Related]
2. [Positron emission tomography with 18F-fluorodeoxyglucose in patients with uterine sarcoma].
Rebollo Aguirre AC; Ramos Font C; Bellón Guardia ME; Cabello García D; Gallego Peinado M; Rodríguez Fernández A; Llamas Elvira JM
Rev Esp Med Nucl; 2007; 26(4):189-95. PubMed ID: 17662185
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging.
Umesaki N; Tanaka T; Miyama M; Kawamura N; Ogita S; Kawabe J; Okamura T; Koyama K; Ochi H
Gynecol Oncol; 2001 Mar; 80(3):372-7. PubMed ID: 11263934
[TBL] [Abstract][Full Text] [Related]
4. Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas.
Sung PL; Chen YJ; Liu RS; Shieh HJ; Wang PH; Yen MS; Wen KC; Shen SH; Lai CR; Yuan CC
Eur J Gynaecol Oncol; 2008; 29(3):246-51. PubMed ID: 18592788
[TBL] [Abstract][Full Text] [Related]
5. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of preoperative ¹⁸F-FDG PET/CT in uterine leiomyosarcoma.
Park JY; Lee JW; Lee HJ; Lee JJ; Moon SH; Kang SY; Cheon GJ; Chung HH
J Gynecol Oncol; 2017 May; 28(3):e28. PubMed ID: 28382795
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography imaging in uterine sarcomas: systematic review and meta-analysis of the literature.
Sadeghi R; Zakavi SR; Hasanzadeh M; Treglia G; Giovanella L; Kadkhodayan S
Int J Gynecol Cancer; 2013 Oct; 23(8):1349-56. PubMed ID: 23945203
[TBL] [Abstract][Full Text] [Related]
8. Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging.
Sharma P; Kumar R; Singh H; Jeph S; Sharma JB; Jain SK; Sharma DN; Bal C; Malhotra A
Nucl Med Commun; 2012 Feb; 33(2):185-90. PubMed ID: 22107993
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
10. Role of
Albano D; Zizioli V; Treglia G; Odicino F; Giubbini R; Bertagna F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):10-16. PubMed ID: 30396849
[TBL] [Abstract][Full Text] [Related]
11. Value of 18F-FDG PET/CT imaging in the staging, restaging, monitoring of response to therapy and surveillance of uterine leiomyosarcomas.
Bélissant O; Champion L; Thevenet H; Weinmann P; Alberini JL
Nucl Med Commun; 2018 Jul; 39(7):652-658. PubMed ID: 29683931
[TBL] [Abstract][Full Text] [Related]
12. 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma.
Ho KC; Lai CH; Wu TI; Ng KK; Yen TC; Lin G; Chang TC; Wang CC; Hsueh S; Huang HJ
Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):484-92. PubMed ID: 17952435
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
14. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
15. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
16. Uterine leiomyosarcoma metastatic to thyroid shown by
Gauthé M; Testart Dardel N; Nascimento C; Trassard M; Banal A; Alberini JL
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):113-115. PubMed ID: 27777040
[TBL] [Abstract][Full Text] [Related]
17. Fluorine-18-fluorodeoxyglucose PET/CT for the evaluation of suspected recurrent uterine leiomyosarcomas.
Kao YH; Saad U; Tan AE; Magsombol BM; Padhy AK
Acta Radiol; 2011 May; 52(4):463-6. PubMed ID: 21498277
[TBL] [Abstract][Full Text] [Related]
18. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT.
Kitajima K; Murakami K; Yamasaki E; Domeki Y; Kaji Y; Morita S; Suganuma N; Sugimura K
Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):362-72. PubMed ID: 18931841
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography.
Jadvar H; Tatlidil R; Garcia AA; Conti PS
Clin Radiol; 2003 Mar; 58(3):215-21. PubMed ID: 12639527
[TBL] [Abstract][Full Text] [Related]
20. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma.
Johnson GR; Zhuang H; Khan J; Chiang SB; Alavi A
Clin Nucl Med; 2003 Oct; 28(10):815-20. PubMed ID: 14508272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
